null

Additional Information

Additional Information

Account Navigation

Account Navigation

Currency - All prices are in AUD

Currency - All prices are in AUD
 Loading... Please wait...
The Natural Therapy Shop

N-Acetylcysteine as Adjuvant Therapy for COVID-19

Posted by Kon Ken Wong12, Shaun Wen Huey Lee3456, Kok Pim Kua7 on

N-Acetylcysteine as Adjuvant Therapy for COVID-19 - A Perspective on the Current State of the Evidence

Kon Ken Wong12, Shaun Wen Huey Lee3456, Kok Pim Kua7

Affiliations

Free PMC article

Abstract

The looming severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a long-lasting pandemic of coronavirus disease 2019 (COVID-19) around the globe with substantial morbidity and mortality. N-acetylcysteine, being a nutraceutical precursor of an important antioxidant glutathione, can perform several biological functions in mammals and microbes. It has consequently garnered a growing interest as a potential adjunctive therapy for coronavirus disease. Here, we review evidence concerning the effects of N-acetylcysteine in respiratory viral infections based on currently available in vitro, in vivo, and human clinical investigations. The repurposing of a known drug such as N-acetylcysteine may significantly hasten the deployment of a novel approach for COVID-19. Since the drug candidate has already been translated into the clinic for several decades, its established pharmacological properties and safety and side-effect profiles expedite preclinical and clinical assessment for the treatment of COVID-19. In vitro data have depicted that N-acetylcysteine increases antioxidant capacity, interferes with virus replication, and suppresses expression of pro-inflammatory cytokines in cells infected with influenza viruses or respiratory syncytial virus. Furthermore, findings from in vivo studies have displayed that, by virtue of immune modulation and anti-inflammatory mechanism, N-acetylcysteine reduces the mortality rate in influenza-infected mice animal models. The promising in vitro and in vivo results have prompted the initiation of human subject research for the treatment of COVID-19, including severe pneumonia and acute respiratory distress syndrome. Albeit some evidence of benefits has been observed in clinical outcomes of patients, precision nanoparticle design of N-acetylcysteine may allow for greater therapeutic efficacy.

Keywords: N-acetylcysteine; SARS-CoV-2; COVID-19; T lymphocytes; anti-inflammatory response; antioxidant; antiviral effect; clinical translation; coronavirus; engineering nanoparticles; glutathione; immune modulating activity; repurposing approved drugs; respiratory viral diseases; virus infected cells.

© 2021 Wong et al.

Conflict of interest statement

The authors declared that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1

Schematic representation of the possible…

Similar articles

Cited by 3 articles

References

    1. Blumenthal D, Fowler EJ, Abrams M, Collins SR. Covid-19 — implications for the Health Care System. N Eng J Med. 2020;383(15):1483–1488. doi:10.1056/NEJMsb2021088 - DOI - PubMed
    1. Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Eng J Med. 2020;383(18):1757–1766. doi:10.1056/NEJMcp2009249 - DOI - PubMed
    1. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Eng J Med. 2020;382(13):1199–1207. doi:10.1056/NEJMoa2001316 - DOI - PMC - PubMed
    1. Hassan AO, Case JB, Winkler ES, et al. A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. Cell. 2020;182(3):744–753.e4. doi:10.1016/j.cell.2020.06.011 - DOI - PMC - PubMed
    1. Sariol A, Perlman S. Lessons for COVID-19 Immunity from Other Coronavirus Infections. Immunity. 2020;53(2):248–263. doi:10.1016/j.immuni.2020.07.005 - DOI - PMC - PubMed

  • NAC and COVID
  • NAC respiratory
  • NAC treatment for COVID
comments powered by Disqus